Pfizer Inc. (PFE)

NYSE: PFE · USD

$29.5

-0.34 (-1.1%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-09-26

Our latest published analysis: PFE rated Reduce

Pfizer Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$25.8 / share

Potential value

$28.9 / share

Upside to FV

-9.9%

from $29.5

Moat

6.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$161.9B
Revenue (ttm)	63.7B
Net income (ttm)	4.3B
EPS (ttm)	$0.76
Shares out	5.7B
P/E (trailing)	38.8x
P/E (forward)	9.7x
Dividend	$1.72 (5.86%)
Volume	20,724,989
Beta	0.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 63.7B
Net income (ttm): 4.3B
EPS (ttm): $0.76
P/E (trailing): 38.8x
P/E (forward): 9.7x
Market cap: $161.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$73.64B	$91.79B	$50.91B	$63.63B	$62.58B	-4.0%
Gross profit	$46.88B	$62.09B	$30.34B	$41.85B	$44.01B	-1.6%
Operating income	$25.60B	$35.97B	$3.27B	$11.11B	$10.19B	-20.6%
Net income	$21.98B	$31.37B	$2.12B	$8.03B	$7.77B	-22.9%
EPS (diluted)	$3.85	$5.47	$0.37	$1.41	$1.36	-22.9%
EBITDA	$30.79B	$41.03B	$9.56B	$18.13B	$15.10B	-16.3%
R&D	$13.83B	$11.43B	$10.58B	$10.74B	$11.98B	-3.5%
SG&A	$12.70B	$13.68B	$14.77B	$14.73B	$13.79B	+2.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	持有
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	强力买入
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	买入

Base and Bull scenarios

Base60%

Price target

$25.83

-9.9% from spot

The Base scenario reflects the modal expected operating trajectory. Management delivers planned net cost savings across manufacturing and corporate functions, successfully stabilizing operating margins at normalized levels. However, patent expirations on core mature blockbusters cause moderate revenue contraction before pipeline launches take effect post-transition. Capital allocation remains dedicated to debt reduction and dividend maintenance. This path targets $25.83 with an estimated probability of 60.0%, representing a return of -9.9% from $28.67 to Fair value of $25.83. This path is confirmed by revenue tracking guided ranges and leverage declining steadily toward target levels.

Restructuring delivers planned cumulative net cost savings across operations
Loss of exclusivity results in moderate top-line contraction during transition years
Capital allocation prioritizes debt reduction and dividend maintenance

Bull20%

Price target

$28.85

+0.6% from spot

Under the Bull scenario, Pfizer accelerates execution of its operational cost reduction program while commercial oncology launches exceed expectations. Operating margins expand beyond normalized levels as manufacturing efficiencies take hold. Label expansions in oncology and promising early data from metabolic combination trials catalyze multiple expansion toward peer averages. This path targets $28.85 with an estimated probability of 20.0%, offering an expected return of 0.6% compared to $28.67. Investors would confirm this path through consecutive quarters of margin outperformance and clinical label expansions by FY2027.

Operational restructuring achieves targeted net cost reductions ahead of schedule
Commercial oncology uptake offsets patent expiration headwinds across legacy franchises
Valuation multiple expands toward broader biopharmaceutical peer averages

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($25.83). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.0%	1.5%	2.0%	2.5%	3.0%
6.3%	$26.4	$26.4	$26.4	$26.4	$26.4
6.8%	$26.1	$26.1	$26.1	$26.1	$26.1
7.3%	$25.8	$25.8	$25.8	$25.8	$25.8
7.8%	$25.6	$25.6	$25.6	$25.6	$25.6
8.3%	$25.3	$25.3	$25.3	$25.3	$25.3

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E9.7

P25 n/aP50 n/aP75 n/a

Trailing P/E36.9

P25 n/aP50 n/aP75 n/a

ROE5

P25 n/aP50 n/aP75 n/a

ROIC13.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PFE indicators

Market & fundamental data

Available fields

282

Groups with data

Currency

USD

Showing 282 of 282 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000078003
Company name	Pfizer Inc.
Country	United States
Country code	US
CUSIP number	717081103
Earnings date	2026-11-03
Earnings time	bmo
Employees	75,000
Employees change	-6,000
Employees growth	-7.41%
Enterprise value	$219.7B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-28
First seen	2026-05-09
Fiscal year end	December
Founded	1849
In index	SP500
Industry	Drug Manufacturers - General
Is primary listing	Yes
Is SPAC	No
ISIN number	US7170811035
Last 10-K release date	2026-02-26
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	1999-07-01
Last stock split type	Forward
Market cap	$167.9B
Market cap category	Large-Cap
Next earnings date	2026-11-03
Options	Yes
Price	$29.46
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	PFE
Tags	weight-loss
U.S. state	New York
Website	https://www.pfizer.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	9.66x
Average P/E ratio (10Y)	18.97x
Average P/E ratio (3Y)	26.74x
Average P/E ratio (5Y)	19.53x
Earnings yield	2.58%
EV/Earnings	50.49x
EV/EBIT	11.61x
EV/EBITDA	8.62x
EV/FCF	19.92x
EV/Sales	3.44x
FCF / EV yield	5.02%
FCF yield	6.58%
Forward EV/Sales	3.58x
Forward P/E	10.66x
Forward P/S	2.73x
Graham number	15.98658
Graham upside	-45.46%
Industry forward P/E	18.47x
Industry P/E	35.8x
Lynch fair value	$3.80
Lynch upside	-87.04%
P/(FCF - SBC) ratio	16.64x
P/(OCF - SBC) ratio	13.41x
P/B ratio	1.99x
P/E ratio	38.77x
P/FCF ratio	15.21x
P/OCF ratio	12.47x
P/S ratio	2.62x
Price/EBITDA ratio	6.58x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	29.58%
EBITDA margin	39.85%
FCF margin	17.25%
Gross margin	74.72%
Operating margin	29.58%
Pretax margin	6.61%
Profit margin	6.8%
Profit per employee	$57,787
Profitable years	35
Revenue per employee	$849,280
ROA	5.78%
ROA (5Y)	7.03%
ROCE	11.18%
ROE	5.01%
ROE (5Y)	17.68%
ROIC	13.49%
ROIC (5Y)	18.62%
SBC / revenue	1.49%
Tax / revenue	-0.26%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-59.88%
EPS growth 10Y	-3.88%
EPS growth 3Y	-41.3%
EPS growth 5Y	-19.56%
EPS growth years	0
FCF growth	-11.68%
FCF growth (QoQ)	-86.14%
FCF growth 3Y	0.99%
FCF growth 5Y	-12.27%
Gross profit growth	2.68%
Gross profit growth (Q)	2.04%
Gross profit growth 3Y	-4.76%
Gross profit growth 5Y	3.85%
Net income growth	-59.69%
Net income growth 3Y	-41.34%
Net income growth 5Y	-19.42%
Net income growth years	0
OCF growth	-11.77%
OCF growth (QoQ)	-68.07%
OCF growth 10Y	-1.34%
OCF growth 3Y	-2.73%
OCF growth 5Y	-10.66%
Operating income growth	11.09%
Operating income growth (Q)	-0.31%
Operating income growth 3Y	-10.2%
Operating income growth 5Y	5.06%
Revenue growth	-0.21%
Revenue growth (Q)	2.6%
Revenue growth (QoQ)	4.03%
Revenue growth 10Y	1.99%
Revenue growth 3Y	-6.7%
Revenue growth 5Y	2.93%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.4B
Depreciation and amortization	$6.5B
EBIT	$18.8B
EBITDA	$25.4B
EPS	$0.76
FCF per share	$1.93
Financing cash flow	$-8.4B
Free cash flow	$11B
Free cash flow minus SBC	$10B
Gross profit	$47.6B
Income taxes	$-164M
Investing cash flow	$-5.7B
Net borrowing	$1.8B
Net cash flow	$-660M
Net income	$4.3B
Operating cash flow minus SBC	$12.5B
Operating income	$18.8B
Revenue	$63.7B
Stock-based compensation	$947M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.22
Book value per share	$14.95
Debt / EBITDA	2.41
Debt / equity	0.74
Debt / FCF	5.78
Goodwill	$71.4B
Interest coverage	6.98
Long-term assets	$159.8B
Long-term liabilities	$83B
Net cash (debt)	$-51.8B
Net cash / market cap	-30.99%
Net debt / EBITDA	2.04
Net debt / equity	0.61
Net debt / FCF	4.71
Piotroski F-Score	7
Property, plant and equipment	$19B
Shareholders' equity	$85.5B
Tangible book value	$-33.3B
Tangible book value per share	$-5.84
Total assets	$201.1B
Total cash	$11.7B
Total debt	$63.5B
Total liabilities	$115.6B
WACC	5.11%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.31
Current assets	$41.4B
Current liabilities	$32.6B
Current ratio	1.27
Inventory turnover	1.49
Net working capital	$-284M
Quick ratio	0.85
Working capital	$8.7B
Working capital turnover	8.67

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.34%
Dividend growth	0%
Dividend growth (10Y)	3.67%
Dividend growth (3Y)	1.6%
Dividend growth (5Y)	1.97%
Dividend growth years	15
Dividend payment date	2026-12-07
Dividend payment years	56
Dividend payout frequency	Quarterly
Dividend per share	$1.72
Dividend yield	5.86%
Ex-dividend date	2026-11-06
FCF payout ratio	89.24%
Last dividend	$0.43
Payout ratio	226.35%
Shareholder yield	5.53%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-9.56%
10Y return CAGR	4.17%
10Y total return	50.38%
150-day SMA	$26.76
15Y price change	48.06%
15Y return CAGR	7.44%
15Y total return	193.51%
1D price change	-1.14%
1M price change	2.46%
1M total return	2.46%
1W price change	-1.59%
1W total return	-1.59%
1Y price change	18.59%
1Y return CAGR	26.93%
1Y total return	26.91%
20-day SMA	$28.94
200-day SMA	$26.75
20Y price change	7.92%
20Y return CAGR	5.14%
20Y total return	172.71%
3M price change	19.07%
3M total return	19.07%
3Y price change	-2.44%
3Y return CAGR	5.77%
3Y total return	18.32%
50-day SMA	$28.46
50-day SMA vs 200-day SMA	50over200
52-week high	$30.44
52-week high date	2026-10-22
52-week low	$23.62
52-week low date	2026-07-06
5Y price change	-31.64%
5Y return CAGR	-2.29%
5Y total return	-10.93%
6M price change	9.65%
6M total return	13.41%
All-time high	$61.71
All-time high date	2021-12-20
All-time low	$0.40
All-time low date	1968-03-14
Average true range (ATR)	$0.55
Average volume	28.4M
Beta (1Y)	0.22
Beta (2Y)	0.44
Beta (5Y)	0.28
Change from 52-week high	-3.22%
Change from 52-week low	24.73%
Change from all-time high	-52.4%
Change from all-time low	7,321.68%
Change from open	-0.03%
Day's gap	-1.11%
Dollar volume	$610.6M
High price	$29.82
Low price	$29.23
Monthly RSI	55.59
Open price	$29.47
Position in 52-week range	38.98%
Premarket change	-0.94%
Premarket close	$29.80
Premarket price	$29.52
Premarket volume	179.1K
Previous close	$29.80
Price vs 150-day SMA	9.79%
Price vs 20-day SMA	1.51%
Price vs 200-day SMA	9.82%
Price vs 50-day SMA	3.23%
Relative volume	0.73
RSI	55.45
Sharpe ratio	1.04
Sharpe ratio (3Y)	0.15
Sharpe ratio (5Y)	-0.12
Sortino ratio	1.9
Sortino ratio (3Y)	0.47
Sortino ratio (5Y)	0.06
Volume	20.7M
Weekly RSI	61.81
YTD price change	17.97%
YTD total return	24.06%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5.7B
Float percentage	99.87%
Shares change (QoQ)	-0.56%
Shares change (YoY)	0.34%
Shares held by insiders	0.03%
Shares held by institutions	68.08%
Shares outstanding	5.7B
Short % of float	2.42%
Short % of shares	2.42%
Short ratio	4.2 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	463

Deeper analysis on PFE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this PFE report

What is the latest published PFE stock rating?

Pfizer Inc. is shown with Reduce in the latest published report, analyzed 2026-09-26. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PFE analysis?

The full latest published report, analyzed 2026-09-26, lives at /stocks/PFE/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for PFE?

The latest published report analyzed 2026-09-26 gives PFE a fair value of USD 26 and a potential value of USD 29. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the PFE page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-26). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ReducePFE · Fair value $25.8-9.9%

Read full analysis →

Category	Score	Reading
Valuation	3.0
Management	7.5
Balance Sheet	6.0
Profitability	5.0
Revenue Growth	4.5
Risk Assessment	7.5
Competitive Moat	6.5
Earnings Quality	6.0
Capital Efficiency	6.5

Pfizer Inc. (PFE)

Our latest published analysis: PFE rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · PFE

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All PFE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on PFE

Frequently asked questions

评级历史